Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tailored strategies to overcome third-generation TKI resistance in EGFR-mutated non-small cell lung cancer.

Expert opinion on therapeutic targets - 1 Jul 2026

Saporita Isabella, Farinea Giovanni, Lombardi Elisa, Bironzo Paolo, Novello Silvia, Passiglia Francesco

Abstract excerpt

INTRODUCTION: In the era of precision medicine, targeting resistance mechanisms is a rational approach to optimize treatment management based on tumor molecular profiling, with the goal of improving clinical outcomes. However, the role of tailored strategies in the treatment algorithm of EGFR-mutated NSCLC remains incompletely defined. AREAS COVERED: This review provides an overview of resistance mechanisms to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Molecular Targeted Therapy

Share to Precision Medicine

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 42473726
DOI: 10.1080/14728222.2026.2706458

Genes

EGFR
MET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tailored strategies to overcome third-generation TKI resistance in EGFR-mutated non-small cell lung cancer.PMID 42473726Read ↗

Strategies Beyond 3rd EGFR‐TKI Acquired Resistance: Opportunities and ChallengesSemantic proximity Read ↗

Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung CancerSemantic proximity Read ↗

Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies.Semantic proximity Read ↗

Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance.Semantic proximity Read ↗

Current and Emerging Treatment Landscape of Common EGFR-Mutated Advanced Non-small Cell Lung Cancer.Semantic proximity Read ↗

Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies.Semantic proximity Read ↗

Recent advances in EGFR-targeted therapies for non-small cell lung cancer.Semantic proximity Read ↗

New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer.Semantic proximity Read ↗

EGFR mutations in non‑small cell lung cancer: Classification, characteristics and resistance to third‑generation EGFR‑tyrosine kinase inhibitors (Review)Semantic proximity Read ↗

Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.